Company: GANX
Filing Date: 2025-11-07
Form Type: S-3/A
Source: 0001104659-25-108472
Chunk: 38

Company: Gain Therapeutics, Inc.
Filing Date: 2025-11-07
Form: S-3/A
Chunk 38
---
The SEC allows us to “incorporate by reference” information that we file with it into this prospectus, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information contained in this prospectus and any accompanying prospectus supplement.

We incorporate by reference the documents listed below that we have previously filed with the SEC:

•

Our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 27, 2025;

•

Our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 and June 30, 2025 , filed with the SEC on May 14, 2025and August 12, 2025, respectively;

•

The information incorporated by reference into the Form 10-K for the year ended December 31, 2024from our definitive proxy statement on Schedule 14A, filed with the SEC on April 29, 2025;

•

Our Current Reports on Form 8-K filed with the SEC on January 7, 2025, January 15, 2025, April 10, 2025, June 24, 2025, June 30, 2025, July 17, 2025, October 6, 2025and October 9, 2025(other than any portions thereof deemed furnished and not filed); and

•

The description of our common stock, par value $0.0001 per share, contained in our Form 8-A filed on March 17, 2021, including any amendment or report filed for the purpose of updating such description, including the Description of Securities filed as Exhibit 4.1to our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 27, 2025.

All reports and other documents that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial filing of the registration statement and prior to effectiveness of the registration statement, and after the date of this prospectus but prior to the termination or completion of the offering of the securities hereunder will also